Follow

"So let me say two things immediately about the now-published results for lecanemab, the latest attempt at anti-amyloid antibody therapy for Alzheimer’s. I think that both of these are true: the numbers are the best that I have yet seen for such an antibody, and at the same time I doubt if the drug will actually make a difference in the treatment of ’s."
- Derek Lowe

science.org/content/blog-post/

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.